Aqueductal Stenosis
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study.
|
30712878 |
2019 |
Focal glomerulosclerosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Glomerular nonmuscle-type myosin heavy-chain isoform gene expression in glomerulosclerosis.
|
9678433 |
1998 |
Hyalinosis, Segmental Glomerular
|
0.300 |
Biomarker
|
disease |
CTD_human |
Glomerular nonmuscle-type myosin heavy-chain isoform gene expression in glomerulosclerosis.
|
9678433 |
1998 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Myosin X is required for efficient melanoblast migration and melanoma initiation and metastasis.
|
29993000 |
2018 |
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
BACKGROUND The myosin heavy chain 10 or MYH10 gene encodes non-muscle myosin II B (NM IIB), and is involved in tumor cell migration, invasion, extracellular matrix (ECM) production, and epithelial-mesenchymal transition (EMT).
|
30552850 |
2018 |
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis.
|
24921915 |
2014 |
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
|
24487586 |
2014 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MYH10 expression was down-regulated following siMYH10 plasmid interference, which also inhibited glioma cell migration and invasion.
|
30552850 |
2018 |
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These data support the conclusion that MYH10‑mediated cell migration and invasion act in conjunction with PIF to promote the trophoblast invasion procedure.
|
29286136 |
2018 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
|
24487586 |
2014 |
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis.
|
24921915 |
2014 |
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
|
24487586 |
2014 |
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
|
24487586 |
2014 |
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis.
|
24921915 |
2014 |
Aortic Aneurysm
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, using weighted gene coexpression analysis, our study indicates that CLU, DES, MYH10, and FBLN5 were identified and validated to be related to TAA and might be candidate biomarkers or therapeutic targets for TAA.
|
31489966 |
2020 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Their less responsive sister paralogs-myosin IIB (MYH10), α-actinin 1, and filamin A-had lower expression differential or disappeared with cancer progression.
|
31358530 |
2019 |
Intraocular pressure disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
CK-666 and shMyo10-silencing lentivirus caused a significant reduction in outflow rates in anterior segment perfusion culture, an ex vivo method to study intraocular pressure regulation.
|
30807639 |
2019 |
Cyanosis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Myh10 mutant pups exhibit cyanosis and respiratory distress, and die shortly after birth from differentiation defects in alveolar epithelium and mesenchyme.
|
30389913 |
2018 |
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate the effects of the MYH10 gene on normal human glial cells and glioma cell lines in vitro, by gene silencing, and to determine the signaling pathways involved.
|
30552850 |
2018 |
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Myh10 deficiency leads to defective extracellular matrix remodeling and pulmonary disease.
|
30389913 |
2018 |
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Myosin X is required for efficient melanoblast migration and melanoma initiation and metastasis.
|
29993000 |
2018 |
Pulmonary Emphysema
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our findings reveal critical roles for Myh10 in alveologenesis at least in part via the regulation of ECM remodeling, which may contribute to the pathogenesis of emphysema.
|
30389913 |
2018 |
Squamous cell carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among these the non-muscle myosin 10 (MYO10) showed the highest upregulation in a LUSC patient cohort of the Cancer Genome Atlas (TCGA).
|
29934580 |
2018 |
Respiratory distress
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Myh10 mutant pups exhibit cyanosis and respiratory distress, and die shortly after birth from differentiation defects in alveolar epithelium and mesenchyme.
|
30389913 |
2018 |
Hydronephrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we report that ND/UB lineage-specific deletion of Myh9/Myh10 in mice caused severe hydroureter/hydronephrosis at birth.
|
28478097 |
2017 |